Literature DB >> 28432376

MDMA does not alter responses to the Trier Social Stress Test in humans.

Anya K Bershad1,2, Melissa A Miller1, Harriet de Wit3.   

Abstract

RATIONALE: ±3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") is a stimulant-psychedelic drug with unique social effects. It may dampen reactivity to negative social stimuli such as social threat and rejection. Perhaps because of these effects, MDMA has shown promise as a treatment for post-traumatic stress disorder (PTSD). However, the effect of single doses of MDMA on responses to an acute psychosocial stressor has not been tested.
OBJECTIVES: In this study, we sought to test the effects of MDMA on responses to stress in healthy adults using a public speaking task. We hypothesized that the drug would reduce responses to the stressful task.
METHODS: Volunteers (N = 39) were randomly assigned to receive placebo (N = 13), 0.5 mg/kg MDMA (N = 13), or 1.0 mg/kg MDMA (N = 13) during a stress and a no-stress session. Dependent measures included subjective reports of drug effects and emotional responses to the task, as well as salivary cortisol, heart rate, and blood pressure.
RESULTS: The stress task produced its expected increase in physiological responses (cortisol, heart rate) and subjective ratings of stress in all three groups, and MDMA produced its expected subjective and physiological effects. MDMA alone increased ratings of subjective stress, heart rate, and saliva cortisol concentrations, but contrary to our hypothesis, it did not moderate responses to the Trier Social Stress Test.
CONCLUSIONS: Despite its efficacy in PTSD and anxiety, MDMA did not reduce either the subjective or objective responses to stress in this controlled study. The conditions under which MDMA relieves responses to negative events or memories remain to be determined.

Entities:  

Keywords:  Anxiety; Cortisol; MDMA; Stress; Trier Social Stress Test

Mesh:

Substances:

Year:  2017        PMID: 28432376      PMCID: PMC5984654          DOI: 10.1007/s00213-017-4621-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  44 in total

1.  'Ecstasy' as a social drug: MDMA preferentially affects responses to emotional stimuli with social content.

Authors:  Margaret C Wardle; Matthew G Kirkpatrick; Harriet de Wit
Journal:  Soc Cogn Affect Neurosci       Date:  2014-03-27       Impact factor: 3.436

2.  Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.

Authors:  G J H Dumont; F C G J Sweep; R van der Steen; R Hermsen; A R T Donders; D J Touw; J M A van Gerven; J K Buitelaar; R J Verkes
Journal:  Soc Neurosci       Date:  2009       Impact factor: 2.083

Review 3.  Assessing salivary cortisol in large-scale, epidemiological research.

Authors:  Emma K Adam; Meena Kumari
Journal:  Psychoneuroendocrinology       Date:  2009-07-31       Impact factor: 4.905

4.  Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitary-adrenal axis.

Authors:  C Kirschbaum; B M Kudielka; J Gaab; N C Schommer; D H Hellhammer
Journal:  Psychosom Med       Date:  1999 Mar-Apr       Impact factor: 4.312

5.  The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting.

Authors:  C Kirschbaum; K M Pirke; D H Hellhammer
Journal:  Neuropsychobiology       Date:  1993       Impact factor: 2.328

6.  Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Authors:  M Mas; M Farré; R de la Torre; P N Roset; J Ortuño; J Segura; J Camí
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

7.  Prosocial effects of MDMA: A measure of generosity.

Authors:  Matthew Kirkpatrick; Andrew W Delton; Theresa E Robertson; Harriet de Wit
Journal:  J Psychopharmacol       Date:  2015-03-03       Impact factor: 4.153

8.  A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy").

Authors:  M R Thompson; P D Callaghan; G E Hunt; J L Cornish; I S McGregor
Journal:  Neuroscience       Date:  2007-03-23       Impact factor: 3.590

9.  Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others.

Authors:  Gillinder Bedi; David Hyman; Harriet de Wit
Journal:  Biol Psychiatry       Date:  2010-10-14       Impact factor: 13.382

10.  The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Authors:  Michael C Mithoefer; Mark T Wagner; Ann T Mithoefer; Lisa Jerome; Rick Doblin
Journal:  J Psychopharmacol       Date:  2010-07-19       Impact factor: 4.153

View more
  5 in total

1.  Effects of Intranasal Oxytocin on Stress-Induced Cigarette Craving in Daily Smokers.

Authors:  Kathryne Van Hedger; Anya K Bershad; Royce Lee; Harriet de Wit
Journal:  Nicotine Tob Res       Date:  2020-01-27       Impact factor: 4.244

Review 2.  Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon.

Authors:  Kawther N Elsouri; Sahand Kalhori; Diego Colunge; Grant Grabarczyk; George Hanna; Cassidy Carrasco; Andy Aleman Espino; Andres Francisco; Bradley Borosky; Bassem Bekheit; Maha Ighanifard; Andrea A Astudillo; Michelle Demory Beckler
Journal:  Cureus       Date:  2022-05-23

Review 3.  Pharmacological challenge studies with acute psychosocial stress.

Authors:  Kathryne Van Hedger; Anya K Bershad; Harriet de Wit
Journal:  Psychoneuroendocrinology       Date:  2017-08-22       Impact factor: 4.905

Review 4.  Modulation of Social Cognition via Hallucinogens and "Entactogens".

Authors:  Katrin H Preller; Franz X Vollenweider
Journal:  Front Psychiatry       Date:  2019-12-03       Impact factor: 4.157

5.  A Systematic Review of the MDMA Model to Address Social Impairment in Autism.

Authors:  Devahuti Chaliha; John C Mamo; Matthew Albrecht; Virginie Lam; Ryu Takechi; Mauro Vaccarezza
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.